Sort
326,823 grants matching “clinical trial”
Evaluation of Multi Modality Breast Imaging
$2,440,428University Of Pennsylvania · P01 · FY2004 · CA
Maternal and infant immunization to eliminate breast milk transmission of HIV-1
$2,440,281Sallie R. Permar · Duke University · P01 · FY2015 · AI
Development of a Potent and Highly Selective NaV1.7 Inhibitor for the Treatment of Acute Pain with the Goal of Reducing Opioid Use and Preventing Opioid Use Disorders
$2,440,102John Cureton Hunter · Siteone Therapeutics, Inc. · UG3 · FY2020 · DA
Notch-Mediated Expansion of Cord Blood Progenitors for Stem Cell Transplant
$2,440,031Colleen Delaney · Fred Hutchinson Cancer Research Center · P50 · FY2017 · HL
Cancer Center Support Grant (CCSG)
$2,440,011George J Weiner · University Of Iowa · P30 · FY2016 · CA
ZZ-3K3A-201: Safety evaluation of 3K3A-APC in ischemic stroke
$2,439,849Patrick D Lyden · Cedars-Sinai Medical Center · U01 · FY2014 · NS
MEMORIAL SLOAN-KETTERING CANCER GENE THERAPY PROGRAM
$2,439,650Sloan-Kettering Institute For Cancer Res · P01 · FY2004 · CA
Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Moderate to Severe Flares: A Phase 3 Multi-Center, Randomized, Double-Blind, Sham-Controlled Trial
$2,439,584Parambir Singh Dulai · Northwestern University At Chicago · U01 · FY2023 · DK
Trial to Assess Chelation Therapy 2 (TACT2) DCC Competing Renewal
$2,439,270Daniel B Mark · Duke University · U24 · FY2022 · AT
Trial to Reduce IDDM in the Genetically at Risk- study
$2,438,769Mikael Knip · University Of Helsinki · U01 · FY2009 · HD
Mayo Clinic Breast Cancer SPORE
$2,438,534Matthew Philip Goetz · Mayo Clinic Rochester · P50 · FY2017 · CA
SPORE: Targeted Therapies for Glioma
$2,438,174Tracy T Batchelor · Brigham And Women'S Hospital · P50 · FY2019 · CA
Cell-Type Specific Vulnerability to Tauopathy and Its Prevention in Multiple Models
$2,438,130Einar M Sigurdsson · New York University School Of Medicine · RF1 · FY2021 · NS
Intercollaborative Radiation Countermeasure (INTERACT) Consortium for Advanced Development of Medical Countermeasures to Mitigate/Treat Acute and Delayed Radiation Syndromes
$2,438,056France Carrier · University Of Maryland Baltimore · U19 · FY2022 · AI
Systemic Autoimmunity
$2,438,018Mariana Kaplan · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIA · FY2022 · AR
Vascular Subphenotypes of Lung Disease
$2,437,938Mark Thomas Gladwin · University Of Pittsburgh At Pittsburgh · P01 · FY2013 · HL
The Louisiana Clinical Center of Nutrition for Precision Health (LA-NPH)
$2,437,881Eric Ravussin · Lsu Pennington Biomedical Research Ctr · UG1 · FY2024 · HD
Optical Technologies for Cervical Neoplasia
$2,437,591Michele Follen · University Of Tx Md Anderson Can Ctr · P01 · FY2007 · CA
Optical Technologies for Cervical Neoplasia
$2,437,346Michele Follen · University Of Tx Md Anderson Can Ctr · P01 · FY2006 · CA
Brain Tumor Therapeutic Efficacy by Quantitative MR
$2,437,189Brian D. Ross · University Of Michigan At Ann Arbor · P01 · FY2008 · CA
Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)
$2,437,131Joel Moss · National Heart, Lung, And Blood Institute · ZIA · FY2009 · HL
Protection of Ischemic Myocardium
$2,437,090Roberto Bolli · University Of Louisville · P01 · FY2013 · HL
Cancer Center Support Grant
$2,436,664Benjamin G. Neel · New York University School Of Medicine · P30 · FY2015 · CA
Center for the Study of Aphasia Recovery (C-STAR)
$2,436,488Julius Fridriksson · University Of South Carolina At Columbia · P50 · FY2024 · DC
Lentiviral Gene Therapy for Sickle Cell Disease and Immunodeficiency Disorders
$2,436,444Brian P Sorrentino · St. Jude Children'S Research Hospital · P01 · FY2011 · HL